Extrahepatic manifestations in chronic hepatitis C virus carriers

Lupus - Tập 24 Số 4-5 - Trang 469-482 - 2015
Éric Rosenthal1,2, P. Cacoub3,4,5,6
1COREVIH PACA EST, CHU de Nice, France
2Service de Médecine Interne, Hôpital de l’Archet, CHU de Nice, Nice; Université de Nice-Sophia Antipolis, Nice, France
3AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Paris, France
4CNRS, FRE3632, Paris, France
5INSERM, UMR_S 959, Paris, France
6Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France

Tóm tắt

Patients with chronic hepatitis C virus (HCV) infection frequently present with extrahepatic manifestations covering a large spectrum, involving different organ systems leading to the concept of systemic HCV infection. These manifestations include autoimmune phenomena and frank autoimmune and/or rheumatic diseases and may dominate the course of chronic HCV infection. Chronic HCV infection causes liver inflammation affecting the development of hepatic diseases. HCV is also a lymphotropic virus that triggers B cells and promotes favorable conditions for B lymphocyte proliferation, including mixed cryoglobulinemia (MC) and MC vasculitis, which is the most prominent extrahepatic manifestation of chronic HCV infection. HCV may also promote a low-grade chronic systemic inflammation that may affect the development of some extrahepatic manifestations, particularly cardiovascular and cerebral vascular diseases. Recognition of extrahepatic symptoms of HCV infection could facilitate early diagnosis and treatment. The development of direct-acting antiviral agents (DDAs) has revolutionized HCV treatment. DDAs, as well as new B-cell-depleting or B-cell-modulating monoclonal antibodies, will expand the panorama of treatment options for HCV-related extrahepatic manifestations including cryoglobulinemic vasculitis. In this context, a proactive, integrated approach to HCV therapy should maximize the benefits of HCV therapy, even when liver disease is mild.

Từ khóa


Tài liệu tham khảo

Smith BD, 2012, MMWR Recomm Rep, 61, 1

10.1111/j.1478-3231.2008.01934.x

10.1136/gut.2006.113217

U.S. Department of Health and Human Services. Organ Procurement and Transplantation Network. U.S. liver transplants performed: January 1, 1988–April 30, 2008, http://www.optn.org/(accessed 30 July 2009).

10.1002/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D

10.7326/0003-4819-117-7-573

10.1155/2012/509309

10.1002/hep.21672

10.1099/vir.0.023010-0

10.1016/0168-8278(92)90073-X

10.1155/2012/980942

10.1128/JVI.00996-08

10.1136/gut.2008.156307

10.1093/infdis/jis385

10.1002/hep.23020

10.1016/j.jhep.2008.04.012

10.1016/j.jhep.2007.02.010

10.1016/j.jhep.2006.10.017

10.1016/j.jhep.2006.08.020

10.1111/j.1478-3231.2008.01945.x

10.1016/j.dld.2006.06.008

10.1001/archinte.166.19.2101

10.1016/0002-9343(74)90852-3

10.1182/blood-2007-11-122713

Puchner KP, 2009, Gastroenterol, 47, 446

10.1097/MNH.0b013e3282f8afe2

10.1053/j.ajkd.2003.11.020

10.1002/art.10699

10.1016/j.semarthrit.2003.10.001

10.1111/j.1432-2277.2002.tb00090.x

10.3748/wjg.13.6518

10.1097/01.bor.0000198002.42826.c2

10.1016/j.cgh.2010.08.026

10.1182/blood-2003-07-2598

10.1182/blood.V91.6.2062

10.1093/rheumatology/kem132

10.1002/1529-0131(200109)44:9<2118::AID-ART364>3.0.CO;2-X

10.1371/journal.ppat.1001184

10.1016/j.autrev.2007.03.010

10.1002/art.23305

10.1002/art.23759

10.1182/blood-2009-10-248518

10.1146/annurev.immunol.26.021607.090357

10.1056/NEJMoa1105143

10.1182/blood.V81.5.1132.1132

10.1056/NEJM199403173301104

10.1002/art.22168

10.1182/blood-2002-09-2856

10.1182/blood-2002-10-3162

10.1093/ndt/gfh469

10.1136/ard.2006.065565

10.1002/art.34331

10.1002/art.34322

10.1136/ard.2007.081653

10.1182/blood-2009-10-245878

10.1136/annrheumdis-2012-202770

American Association for the Study of Liver Diseases. Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C, http://www.hcvguidelines.org/sites/default/files/full_report.pdf (Accessed July 2014).

10.1016/j.jhep.2013.11.003

10.1097/BOR.0b013e3282f1330c

10.1136/annrheumdis-2013-203883

10.3899/jrheum.081308

Hsu FC, 2003, J Rheumatol, 30, 455

10.1136/ard.61.7.635

10.2165/00063030-200115090-00002

10.1002/hep.22269

10.1038/sj.ijo.0802625

10.1016/j.semarthrit.2003.12.006

10.1517/14656566.6.1.27

10.1016/j.jbspin.2006.05.005

10.1136/ard.2005.038042

Cacoub P, 1997, J Rheumatol, 24, 2139

10.1016/0140-6736(92)91645-O

10.1097/01.md.0000157397.30055.c9

10.1016/S0140-6736(05)66990-5

10.1136/ard.61.6.482

10.1136/ard.53.10.637

10.1002/art.1780390714

10.1097/00005792-200101000-00001

10.1046/j.1365-2796.1999.00414.x

Loustaud-Ratti V, 2001, J Rheumatol, 28, 2245

10.1097/00005792-200001000-00005

10.1097/00042737-199908000-00004

Clifford BD, 1995, Hepatology, 21, 613

10.1016/S0168-8278(02)00067-3

10.1111/j.1601-0825.2007.01436.x

10.1016/S0198-8859(02)00423-8

10.1046/j.1365-2362.2003.01110.x

10.7326/0003-4819-122-3-199502010-00002

10.1016/j.amjmed.2004.01.023

10.1002/(SICI)1096-8652(200006)64:2<107::AID-AJH6>3.0.CO;2-C

10.1016/j.dld.2006.06.008

10.1002/art.20594

10.1182/blood.V82.12.3701.3701

10.1053/j.gastro.2003.09.025

10.1158/1055-9965.EPI-06-0308

10.1001/archinte.165.1.101

10.1182/blood-2004-05-1711

10.1001/jama.297.18.2010

10.1056/NEJMoa013376

10.1111/j.1365-2036.2005.02395.x

10.1002/ijc.23462

10.1182/blood.V93.5.1778

10.1002/ajh.1101

10.1136/ard.2007.085910

10.1182/blood.V91.7.2433

10.4049/jimmunol.174.10.6532

10.1111/j.1365-2141.1995.tb05582.x

10.1073/pnas.0303971101

10.1002/jmv.21388

10.1016/j.autrev.2008.05.005

10.1200/JCO.2005.01.5016

10.1056/NEJM199302183280703

10.1159/000168874

10.1016/j.virol.2005.01.013

10.1016/S0272-6386(03)00024-6

10.1016/S0002-9343(00)00369-7

10.1053/j.ajkd.2012.08.040

10.1111/j.1523-1755.2005.00080.x

10.1681/ASN.2005091006

10.1097/MD.0b013e3181c1750f

Markowitz GS, 1998, J Am Soc Nephrol, 9, 2244, 10.1681/ASN.V9122244

10.1001/archinte.167.12.1271

10.2215/CJN.00470107

Kidney Disease: Improving Global Outcomes (KDIGO), 2008, Kidney Int, 73, S1

10.1016/S0168-8278(05)80631-2

10.4065/75.4.355

10.1002/hep.510290235

10.7326/0003-4819-133-8-200010170-00009

10.1002/hep.510300416

10.2337/diacare.28.10.2548

10.1053/jhep.2003.50291

10.2337/dc05-1995

10.1111/j.1572-0241.2005.40429.x

10.1016/j.diabres.2006.07.008

10.1093/aje/kwm061

10.1111/j.1432-2277.2008.00804.x

10.1177/039139880803100801

10.1053/j.gastro.2010.11.002

10.2337/dc06-0456

10.1002/hep.22703

10.1097/01.mcg.0000190774.91875.d2

10.3851/IMP1298

Baranova A, 2006, Nutrition and health, 291

10.1111/j.1365-2036.2006.03114.x

10.1111/j.1572-0241.2006.00848.x

10.3748/wjg.v11.i12.1848

10.1002/hep.22845

10.1111/j.1572-0241.2003.07640.x

10.1111/j.1365-2036.2005.02596.x

10.1111/j.1464-5491.2005.01646.x

10.1016/S0140-6736(02)07339-7

10.1086/599371

10.1253/circj.CJ-08-0459

10.1136/hrt.2003.018937

10.1111/apt.12234

10.1136/gut.2006.091983

10.1002/hep.23219

Bilora F, 2002, Gastroenterol Clin Biol, 26, 1001

10.1007/s10620-014-3222-3

10.1016/j.jhep.2012.07.045

10.4254/wjh.v5.i10.528

10.1161/STROKEAHA.110.598136

10.1161/01.STR.0000226901.34927.10

10.1016/j.jcv.2009.10.005

10.1016/j.jhep.2005.06.018

10.1053/j.gastro.2011.11.028

10.1016/j.atherosclerosis.2012.01.051

10.1016/j.atherosclerosis.2013.08.003

10.1111/apt.12391

10.1007/s10620-007-9896-z

10.1016/j.jhep.2005.04.006

10.1111/j.1365-2893.2009.01188.x

10.1111/j.1468-1293.2007.00505.x

Casato M, 2005, J Rheumatol, 32, 484

10.1016/j.genhosppsych.2005.06.006

10.1046/j.1365-2893.2002.00364.x

10.1136/gut.2006.100081

10.1136/gut.2005.080267

10.1002/hep.20659

10.1002/hep.21565

10.1111/j.1478-3231.2011.02461.x

10.1016/j.jhep.2014.04.003

10.4088/JCP.v66n0106

10.3851/IMP1566

10.2165/00023210-200519020-00002

Thông tin
Thông tin xuất bản

Lupus

Tập 24 Số 4-5

469-482

Thông tin tác giả